LianBio (NASDAQ: LIAN) operates as a biotechnology company with a focus on the development and distribution of medicines. The company's main offerings include the development of transformative and precision-based therapeutics in areas such as cardiovascular, oncology, ophthalmology, and inflammatory disease. LianBio primarily serves the healthcare industry. It was founded in 2020 and is based in Shanghai, China.
Latest LianBio News
Nov 14, 2023
Nov. 14, 2023 2:09 AM ET LianBio (LIAN) By: Pranav Ghumatkar , SA News Editor LianBio press release (NASDAQ: LIAN ): Q3 GAAP EPS of -$0.22 beats by $0.06. Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022. More on LianBio
LianBio Frequently Asked Questions (FAQ)
When was LianBio founded?
LianBio was founded in 2020.
Where is LianBio's headquarters?
LianBio's headquarters is located at 9th Floor, Kerry Parkside, 1155 Fangdian Road Unit 901-902, Shanghai.
What is LianBio's latest funding round?
LianBio's latest funding round is IPO.
How much did LianBio raise?
LianBio raised a total of $310M.
Who are the investors of LianBio?
Investors of LianBio include Perceptive Advisors, Vida Ventures, Farallon Capital Management, Pfizer, Viking Global Investors and 12 more.